The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Canagliflozin Use Reduces Total Heart Failure Events by 36%
Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.
Patients With Diabetes Need Psychological Care
Survey findings highlight the psychological and psychosocial distress related to having diabetes.
Closed-Loop Tech Improves Daytime Blood Sugar Control for Type 1 Diabetes
More patients achieve international time in range consensus target of greater than 70% with the Advanced system.
Ildiko Lingvay, MD: Predictors of Gastrointestinal Events with Semaglutide
A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.
Comparing Once-Weekly Semaglutide vs Daily Empagliflozin in Type 2 Diabetics
Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.
Vibeke Strand, MD: Important Rheumatology Data Coming Out of EULAR
Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.
Vibeke Strand, MD: Comorbidities Make Treating Psoriatic Arthritis Difficult
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
John Botson, MD: Pegloticase Plus Methotrexate For Gout
A clinical rheumatologist breaks down how the combination therapy can be used to treat uncontrolled gout.
Filgotinib Effective for Patients With Rheumatoid Arthritis
The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.
Tocilizumab Shows Similar Efficacy to Other Targeted Immune Modulators
Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.
Philip Mease, MD: Taking Conferences Virtual in the Age of COVID-19
Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.
Dennis McGonagle, PhD: The Future of Guselkumab for Psoriatic Arthritis
Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.
Philip Mease, MD: The Relationship Between Psoriatic Arthritis and IBD
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Tofacitinib Reduces Psychiatric Disorder Rates in Rheumatoid Arthritis Patients
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
Philip Mease, MD: Upadacitinib Showing Promise Treating Psoriatic Arthritis
Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.
Methotrexate and Pegloticase Treatment Improves Uncontrolled Gout
More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.
Serious Infection More Likely in Older Rheumatoid Arthritis Patients
A team investigated data from trials of tofacitinib, adalimumab, and placebo.
Secukinumab Reduces Spinal Pain for Axial Spondyloarthritis
Study drug also recently showed promise in treating psoriatic arthritis.
Ixekizumab Improves Signs and Symptoms of Psoriatic Arthritis
The safety profile is consistent with previous studies of the ixekizumab.
Upadacitinib Improves Rheumatoid Arthritis Symptoms Over Abatacept
The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.
Tofacitinib Bests Placebo in Psoriatic Arthritis Trial
Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.
Upadacitinib Outperforms Placebo, Adalimumab for Psoriatic Arthritis
The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.
Belimumab Safe and Effective Treating Systemic Lupus Erythematosus
Asian countries regularly see higher rates of SLE prevalence globally.
Higher Doses of Upadacitinib Increase Rate of Serious Infections
The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.
Netakimab Rapidly Improves Axial Disease
The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.
Nanoparticle Treatment Showing Promise Against Rheumatoid Arthritis
In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.
Positive Results Treating Active Psoriatic Arthritis with Upadacitinib
In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.
Ixekizumab Improves Psoriatic Arthritis Pain, Fatigue
Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.
RA Patients With ACPA or RF Positivity Less Likely to Discontinue Abatacept
The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.
Gut Microbiome Hints at Lupus Nephritis Disease Activity
Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.